Phio Pharmaceuticals Corp's stock is trading higher after the company announced the presentation of two preclinical studies of its INTASYL compound PH-894 at a conference. The first study shows that melanoma cells treated with PH-894 become more recognizable to immune cells, potentially increasing their destruction by T cells. The second study demonstrates PH-894's effectiveness as an antitumor cytotoxic agent, killing various human cancer cell lines. PHIO shares are up 64.0%.